Shin Nippon Biomedical Laboratories   Report issue

For profit Phase 1 Phase 2
Founded: Tokyo Japan (1957)

Organization Overview

First Clinical Trial
2006
NCT00364039
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2017

Timeline

NOW
  • Now

Alternative names

Shin Nippon Biomedical Laboratories, Ltd. | SNBL | SNBL, Baltimore,MD 21201 | SNBL Clinical Pharmacology Center | SNBL Clinical Pharmacology Center, Inc. | SNBL Clinical Pharmacology Center Inc, Baltimore, MD | SNBL Pharmacology Center

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Acute Pain (Phase 2)

Ankle Injuries (Phase 2)

Anthrax (Phase 2)

Caliciviridae Infections (Phase 2)

Campylobacter Infections (Phase 2)

Carcinoma (Phase 1)

Cytomegalovirus Infections (Phase 1)

Gastroenteritis (Phase 2)

Hemorrhagic Fevers, Viral (Phase 1)

Infections (Phase 2)

Influenza, Human (Phase 1)

Marburg Virus Disease (Phase 1)

Nasopharyngeal Carcinoma (Phase 1)

Nausea (Phase 2)

Schizophrenia (Phase 1)

Virus Diseases (Phase 2)

Vomiting (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 20
  • # of Trial APIs: 21